cell-therapy

Scientific Agent for evidence-grounded evaluation of cell-therapy products.

Interactive dashboard tracking CAR-T, CAR-NK, CAAR-T, and CAR-γδ T clinical trials across heme- and solid-onc from ClinicalTrials.gov v2. Sister app to Rheumatology-CAR-T-Trials-Monitor.

single cell RNA-seq analysis of human gastric insulin-secreting (GINS) organoids

Cell therapy manufacturing analytics portfolio — CPV dashboards, OOT investigation, and golden batch monitoring

Sana Biotechnology * — independent third-party profile of a public API surface, by API Evangelist. Sana Biotechnology is a clinical-stage biotechnology company (NASDAQ: SANA) focused on engineering cells as medicines. Its platforms repair or control genes inside cells and replace missing or damaged cells to address the underlying causes of disease,

ImmuneBridge — independent third-party profile of a public API surface, by API Evangelist. ImmuneBridge is a San Francisco biotech company building a first-in-class integrated screening and manufacturing platform for allogeneic cell therapies. The company screens and expands stem cells from multiple sources (umbilical cord blood, mobilized blood, b

Aspect Biosystems — independent third-party profile of a public API surface, by API Evangelist. Aspect Biosystems is a Vancouver, British Columbia biotechnology company developing Bioprinted Tissue Therapeutics — implantable, allogeneic living tissues designed to replace, repair, or supplement biological function in the body.

SQZ Biotech — independent third-party profile of a public API surface, by API Evangelist. SQZ Biotech is a company surfaced as a portfolio company of gv and added to the API Evangelist network as a stub for enrichment. Sector: life-sciences. This profile is a lead awaiting the enrichment pipeline.

TScan Therapeutics — independent third-party profile of a public API surface, by API Evangelist. TScan Therapeutics (Nasdaq: TCRX) is a clinical-stage biopharmaceutical company based in Waltham, Massachusetts developing T-cell receptor engineered T-cell (TCR-T) therapies for the treatment of patients with cancer.

Abata Therapeutics — independent third-party profile of a public API surface, by API Evangelist. Abata Therapeutics was a biotechnology company developing engineered regulatory T cell (Treg) therapies aimed at restoring immune tolerance in tissue-specific autoimmune and inflammatory diseases, with lead programs directed at progressive multiple scle

Synthekine — independent third-party profile of a public API surface, by API Evangelist. Synthekine is a clinical-stage biotechnology company discovering, developing, and commercializing the next generation of selective cytokine therapeutics. The company believes cytokine therapeutics engineered to be selective can fundamentally change the treatmen

oricell — independent third-party profile of a public API surface, by API Evangelist. Oricell Therapeutics (原启生物) is a Shanghai-based clinical-stage biopharmaceutical company developing cell-based immunotherapies for cancer, including GPC3-targeted CAR-T (Ori-C101) for advanced liver cancer and GPRC5D-targeted CAR-T (OriCAR-017) for relapsed/refrac

novoprotein — independent third-party profile of a public API surface, by API Evangelist. Novoprotein (Suzhou Novoprotein Scientific / 苏州近岸蛋白质科技股份有限公司) is a Chinese biotechnology company specializing in recombinant protein preparation and related life-science reagents and contract research services.

Umoja Biopharma — independent third-party profile of a public API surface, by API Evangelist. Umoja Biopharma is a Seattle-based clinical-stage immuno-oncology company developing in vivo CAR T cell therapies for cancer. Its VivoVec lentiviral platform generates CAR T cells directly in a patient's body, removing the ex vivo manufacturing step of tra

3T Biosciences — independent third-party profile of a public API surface, by API Evangelist. 3T Biosciences is a clinical-stage immunotherapy company based in South San Francisco, developing next-generation T-cell receptor (TCR) therapeutics for solid tumors and other immune-mediated diseases. Founded in 2017 on research from K.

Create — independent third-party profile of a public API surface, by API Evangelist. CREATE Medicines is a Cambridge, Massachusetts biopharmaceutical company developing in vivo CAR (chimeric antigen receptor) cell therapies using mRNA lipid-nanoparticle (mRNA-LNP) delivery.

Cellares — independent third-party profile of a public API surface, by API Evangelist. Cellares is an Integrated Development and Manufacturing Organization (IDMO) for cell therapies, operating a global network of automated "Smart Factories." Its FDA-recognized Cell Shuttle platform delivers high-throughput, end-to-end, cGMP industrial-scale cell th

XellSmart Biomedical — independent third-party profile of a public API surface, by API Evangelist. XellSmart Biomedical (士泽生物医药) is a clinical-stage biotechnology company based in Suzhou and Shanghai, China, founded in 2021 by Dr. Xiang Li. The company develops clinical-grade, allogeneic, off-the-shelf iPSC-derived cell therapies for central nervou

Cell Design Labs — independent third-party profile of a public API surface, by API Evangelist. Cell Design Labs, Inc. was a biotherapeutics company based at 5858 Horton Street, Emeryville, California, that engineered immune cells into "smart, living therapies" for cancer and other diseases.

Orca Bio is a late-stage biotechnology company developing high-precision allogeneic cell therapies for the treatment of cancer and autoimmune diseases. Its approach engineers purified cell populations, including regulatory T cells, to improve patient outcomes while reducing the risks associated with traditional allogeneic transplant.